BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 19138263)

  • 41. Periodontal management of Glanzmann's thrombasthenia: report of 3 cases.
    Kantarci A; Cebeci I; Firatli E; Atamer T; Tuncer O
    J Periodontol; 1996 Aug; 67(8):816-20. PubMed ID: 8866321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Type I Glanzmann thrombasthenia: most common subtypes in North Indians.
    Kannan M; Ahmed RP; Jain P; Kumar R; Choudhry VP; Saxena R
    Am J Hematol; 2003 Oct; 74(2):139-41. PubMed ID: 14508803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rap1b association with the platelet cytoskeleton occurs in the absence of glycoproteins IIb/IIIa.
    White GC; Fischer TH; Duffy CM
    Thromb Haemost; 1998 Apr; 79(4):832-6. PubMed ID: 9569200
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The ex vivo production of human monoclonal antibodies to glycoprotein IIb-IIIa complexes of blood platelets.
    Laroche-Traineau J; Clofent-Sanchez G; Vezon G; Nurden AT
    Hum Antibodies Hybridomas; 1994; 5(3-4):165-77. PubMed ID: 7538808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acquired thrombasthenia due to GPIIb/IIIa-specific platelet autoantibodies.
    Niessner H; Clemetson KJ; Panzer S; Mueller-Eckhardt C; Santoso S; Bettelheim P
    Blood; 1986 Aug; 68(2):571-6. PubMed ID: 3015287
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Homozygous Cys542-->Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia.
    Ruan J; Schmugge M; Clemetson KJ; Cazes E; Combrie R; Bourre F; Nurden AT
    Br J Haematol; 1999 May; 105(2):523-31. PubMed ID: 10233432
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glanzmann thrombasthenia: integrin alpha IIb beta 3 deficiency.
    Tomiyama Y
    Int J Hematol; 2000 Dec; 72(4):448-54. PubMed ID: 11197210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two human antibodies reacting with different epitopes on integrin beta 3 of platelets and endothelial cells.
    Jallu V; Diaz-Ricart M; Ordinas A; Pico M; Vezon G; Nurden AT
    Eur J Biochem; 1994 Jun; 222(3):743-51. PubMed ID: 7517865
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New Insights Into the Treatment of Glanzmann Thrombasthenia.
    Poon MC; Di Minno G; d'Oiron R; Zotz R
    Transfus Med Rev; 2016 Apr; 30(2):92-9. PubMed ID: 26968829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Unusual features in Glanzmann thrombasthenia; proliferation of B-lymphocytes, lead poisoning].
    Bucher U
    Schweiz Med Wochenschr; 1988 Oct; 118(42):1510-27. PubMed ID: 3059486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A unique phenotype of acquired Glanzmann thrombasthenia due to non-function-blocking anti-αIIbβ3 autoantibodies.
    Akuta K; Kashiwagi H; Yujiri T; Nishiura N; Morikawa Y; Kato H; Honda S; Kanakura Y; Tomiyama Y
    J Thromb Haemost; 2019 Jan; 17(1):206-219. PubMed ID: 30388316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Detection of anti-GPIIb-IIIa autoantibodies and its clinical significance in autoimmune thrombocytopenic purpura].
    Tomiyama Y; Kosugi S; Kurata Y
    Rinsho Byori; 1997 Oct; 45(10):934-41. PubMed ID: 9369070
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bone marrow transplantation for Glanzmann's thrombasthenia.
    Johnson A; Goodall AH; Downie CJ; Vellodi A; Michael DP
    Bone Marrow Transplant; 1994 Jul; 14(1):147-50. PubMed ID: 7951102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Constitutional thrombopathies: from the clinical description of rare diseases (Glanzmann thrombasthenia and Bernard-Soulier syndrome) to the development of new antithrombotic agents].
    Caen J; Bellucci S
    Bull Acad Natl Med; 1998; 182(7):1493-502; discussion 1502-3. PubMed ID: 9916343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Rapid detection of platelet glycoprotein IIb, IIIA gene variety by single strand conformation polymorphism analysis].
    Chen F; Coller B; French D
    Zhonghua Yi Xue Za Zhi; 1995 Jun; 75(6):341-3, 382. PubMed ID: 7553144
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunisation against αIIbβ3 and αvβ3 in a type 1 variant of Glanzmann's thrombasthenia caused by a missense mutation Gly540Asp on β3.
    Wihadmadyatami H; Röder L; Berghöfer H; Bein G; Heidinger K; Sachs UJ; Santoso S
    Thromb Haemost; 2016 Aug; 116(2):262-71. PubMed ID: 27098940
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glanzmann's thrombasthenia in North Indians: sub classification and carrier detection by flow cytometry.
    Kannan M; Ahmad F; Yadav BK; Anand M; Jain P; Kumar R; Saxena R
    Platelets; 2009 Feb; 20(1):12-5. PubMed ID: 19172516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel Pro126His beta propeller mutation in integrin alphaIIb causes Glanzmann thrombasthenia by impairing progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi.
    Shen WZ; Ding QL; Jin PP; Wang XF; Jiang YZ; Li SM; Wang HL
    Blood Cells Mol Dis; 2009; 42(1):44-50. PubMed ID: 18976939
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis.
    Fullard JF
    Curr Pharm Des; 2004; 10(14):1567-76. PubMed ID: 15134555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human platelet alloantigen polymorphism in Glanzmann's thrombasthenia and its impact on the severity of the disease.
    Ghosh K; Kulkarni B; Nair S; Shetty S; Mohanty D
    Br J Haematol; 2002 Nov; 119(2):348-53. PubMed ID: 12406067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.